Selected Recent Publications Kuo KT, Mao TL, Jones S, Veras E, Ayhan A, Wang TL, Glas R, Slamon D, Velculescu VE, Kurman RJ, Shih IM. Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma. Am J Pathol, Am J Pathol, 174:1597-1601, 2009. Kuo KT, Guan B, Feng Y, Mao TL, Chen X, Jinawath N, Wang Y, Kurman RJ, Shih IM, and Wang TL. Analysis of DNA copy number alterations in ovarian serous tumors identifies new molecular genetic changes in low-grade and high-grade carcinomas. Cancer Res, 69:4036-4042, 2009. Jinawath N. Nakayama K, Yap K, Thiaville M, Wang TL, Shih IM. NAC-1, a potential stem cell pluripotency factor, contributes to paclitaxel resistance in ovarian cancer through inactivating Gadd45 pathway. Oncogene, 28: 1941-1948, 2009. Choi JH, Sheu J, Guan B, Jinawath N, Markowski P, Wang TL, Shih IM. Functional analysis of 11q13.5 amplicon identifies Rsf-1 (HBXAP) as a gene involved in paclitaxel resistance in ovarian cancer. Cancer Res, 69:1407-1415, 2009. Cho K, Shih IM. Ovarian cancer. Annual Review Pathol, 4:287-313, 2009. Choi J-H, Park JT, Davidson B, Morin PJ,Shih IM, Wang TL. Jagged-1 and Notch3 juxtacrine loop regulates ovarian tumor growth and adhesion. Cancer Res, 68:5716-5723, 2008. Park J. Shih IM, Wang TL. Identification of Pbx1, a potential oncogene, as a Notch3 target gene in ovarian cancer. Cancer Res, 68:8852-60, 2008. Kurman RJ, Visvanathan K, Roden R, Wu TC, Shih IM. Early detection and treatment of ovarian cancer: shifting from early stage to minimal volume of disease based on a new model of carcinogenesis. Am J Obst Gyn, 198:351-356, 2008. Sheu J, Choi JH, Lin A, Yyldyz I, Tsai F-J, Shaul Y, Wang TL, Shih IM. The roles of hSNF2H in the tumor-promoting functions of Rsf-1. Cancer Res, 68:4050-4057, 2008. Salani R, Davidson B, Fiegl M, Huang HY, Marth C, Muller-Holzner E, Gastl G, Hsiao JC, Lin HS, Wang TL, Lin BL, Shih IM. Measurement of cyclin E genomic copy nymber and strand length in cell-free DNA distinguish malignant versus benign effusions. Clin Cancer Res, 13:5805-5809, 2007. Nakayama K, Nakayama N, Wang TL, Shih IM. NAC-1 controls cell growth and survival by repressing transcription of Gadd45GIP1, a candidate tumor suppressor. Cancer Res, 67: 8058-8064, 2007. Shih IM. Gestational trophoblastic neoplasms- pathogenesis and target-based therapy. Lancet Oncology, 8:642-650, 2007. Nakayama K, Nakayama N, Jinawath N, Salani R, Kurman RJ, Shih IM, Wang TL. Amplicon profiles in ovarian serous carcinomas. Int J Cancer, 120: 2613-2617, 2007. Shih IM, Wang TL. Notch signaling, gamma secretase inhibitors and cancer therapy. Cancer Res, 67:1879-1882, 2007 Nakayama K, Nakayama N, Davidson B, Sheu J, Natini Jinawath, Santillan A, Salani R, Bristow RE, Morin PJ, Kurman RJ, Wang TL, Shih IM. A BTB/POZ protein, NAC-1, is related to tumor recurrence and is essential for tumor growth and survival. Proc Natl Acad Sci USA, 103:18739-18744, 2006. Park, JT, Li M, Nakayama K, Mao T-L, Davidson B, Zheng Z, Kurman RJ, Eberhart CG, Shih IM, Wang TL. Notch-3 gene amplification in ovarian cancer. Cancer Res, 66:6312-6318, 2006. Shih IM and Kurman RJ. Molecular pathogenesis of ovarian borderline tumors- new insights and old challenges. Clin Cancer Res, 11:7273-7279, 2005. Shih, I.-M., Sheu, J. J., Santillan, A., Nakayama, K., Yen, M. J., Bristow, R. E., Vang, R., Parmigiani, G., Kurman, R. J., Trope, C. G., Davidson, B. & Wang, T. L. Amplification of a chromatin remodeling gene, Rsf-1/HBXAP, in ovarian carcinoma. (2005) Proc Natl Acad Sci U S A 102, 14004-9. Chen Y-C, Pohl G, Wang TL, Morin PJ, Risberg B, Christesen GB, Yu A, Davidson B, Shih IM. Apolipoprotein E is required for cell proliferation and survival in ovarian cancer. Cancer Res, 65:331-337, 2005. Pohl G, Ho C-L, Kurman RJ, Bristow R, Wang T-L, Shih IM. Inactivation of the MAPK pathway as a potential target-based therapy in ovarian serous tumors with KRAS or BRAF mutations. Cancer Res, 65:1994:2000, 2005. Shih IM and Wang TL. Exploring cancer genome using innovative technologies. Curr Opin Oncol, 17:33-38, 2005. Ho C-L, Kurman RJ, Dehari R, Wang T-L, Shih IM. Mutations of BRAF and KRAS precede the development of ovarian serous borderline tumors. Cancer Res, 64:6915-6918, 2004. Wang T-L, Diaz L, Romans K, Bardelli A, Saha S, Galizia G, Choti M, Donehower R, Parmigiani G, Shih IM, Iacobuzio-Donahue C, Kinzler K, Vogelstein B, Lengauer C, Velculescu V. Digital karyotyping identifies thymidylate synthase amplification as a mechanism of resistance to 5-fluorouracil in metastatic colorectal cancer patients. Proc Natl Acad Sci U S A. 2004 March 2; 101(9): 3089–3094. Shih IM and Kurman RJ. Ovarian tumorigenesis - a proposed model based on morphological and molecular genetic analysis. Am J Pathol, 164: 1511-1518, 2004. Wang BG, Huang H-Y, Chen Y-C, Bristow RE, Kassauei K, Roden R, Sokoll LJ, Chan DW, Shih I-M. Increased plasma DNA integrity in cancer patients. Cancer Res, 63:3966-3968, 2003.
Cover Legend Singer G, Oldt 3rd R, Cohen Y, Wang B, Sidransky D, Kurman RJ, Shih IM. Mutations in BRAF and KRAS Ras characterize the development of low-grade ovarian serous carcinoma. J Natl Can Inst, 95:484-486, 2003. 
Wang T-L, Maierhofer C, Speicher M, Lengauer C, Vogelstein B, Kinzler K, Velculescu V. Digital karyotyping. Proc Natl Acad Sci U S A. 2002 December 10; 99(25): 16156–16161 Chang H-W, Singer G, Cho SR, Sokoll L, Montz F, Roden R, Zhang Z, Chan DW, Kurman RJ, Shih IM. Detection of allelic imbalance by counting alleles in plasma as a diagnostic tool for cancer. J Natl Can Inst, 94:1697-1703, 2002. Singer G, Kurman RJ, Chang H-W, Cho SKR, Shih IM. Diverse tumorigenic pathways in ovarian serous carcinoma. Am J Pathol, 160:1223-1228, 2002.
Shih IM, Torrance C, Sokoll L, Chan DW, Kinzler KW, Vogelstein B. Assessing tumors in living animals through measurement of urinary b-human chorionic gonadotropin. Nature Med, 6:711-714, 2000.
|
